News brief
On October 6, 2026, per EU-Startups, Paris-based WhiteLab Genomics raised $26 million (€23.2M) in a Series B led by AVP, with new investors Yaday Health and Blast Club, to build AI-designed bio-assets for next-generation genomic medicines.
Connected profiles
Explore
Sources · 1Sources & provenance
English text is maintained separately from the original record. Consult the original source before citing a fact.
- www.eu-startups.com ↗Published Oct 6, 2026
Original source text
Names may use phonetic renderings when no English name is supplied. The original wording is retained below.
2026年10月6日，据EU-Startups报道，法国巴黎AI基因组药物公司WhiteLab Genomics完成2600万美元（约2320万欧元）B轮融资，由AVP领投，新投资方Yaday Health与Blast Club加入，用于AI设计的生物资产研发。